An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

NCT ID: NCT02350816

Last Updated: 2021-06-11

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-08
• Study Completion Date: 2019-04-12

Brief Summary

This extension study will allow participants to continue receiving treatment with HGT-1410 and to initiate treatment in patients who received no-treatment in Study HGT-SAN-093, and will evaluate the long-term safety and efficacy of the study drug.

Conditions

Sanfilippo Syndrome; Mucopolysaccharidosis (MPS)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W

Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).

HGT-SAN-093 = NCT02060526

Group Type: ACTIVE_COMPARATOR

HGT-1410

Intervention Type: DRUG

HGT-1410 administered according to Patient Group assignment.

HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W

Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).

Group Type: ACTIVE_COMPARATOR

HGT-1410

Intervention Type: DRUG

HGT-1410 administered according to Patient Group assignment.

no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W

Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).

Group Type: ACTIVE_COMPARATOR

HGT-1410

Intervention Type: DRUG

HGT-1410 administered according to Patient Group assignment.

no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W

Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).

Group Type: ACTIVE_COMPARATOR

HGT-1410

Intervention Type: DRUG

HGT-1410 administered according to Patient Group assignment.

Interventions

HGT-1410

HGT-1410 administered according to Patient Group assignment.

Intervention Type: DRUG

Other Intervention Names

Recombinant Human Heparan N Sulfatase

Eligibility Criteria

Inclusion Criteria

Patients must meet all of the following criteria to be considered eligible for enrollment:

1. Patient has completed through at least the Week 48 visit of Study HGT-SAN-093

2. The patient's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board- (IRB-)/ Independent Ethics Committee- (IEC-) approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, as relevant, must be obtained

Exclusion Criteria

Patients will be excluded from the study if any of the following criteria are met:

1. The patient, if randomized to treatment in Study HGT-SAN-093, has experienced a decline of more than 20 points in the BSID-III cognitive DQ score between Baseline and the Week 48 visit in Study HGT-SAN-093, AND, upon individual evaluation by the Investigator, has been deemed a treatment failure*

2. The patient has experienced, in the opinion of the Investigator, a safety or medical issue that contraindicates treatment with HGT-1410, including but not limited to clinically relevant intracranial hypertension, severe infusion-related reactions after treatment with HGT-1410, uncontrollable seizure disorder

3. The patient has a known hypersensitivity to any of the components of HGT-1410

4. The patient is enrolled in another clinical study, other than HGT-SAN-093, that involves clinical investigations or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study

5. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to airway compromise or other conditions

6. The patient has a condition that is contraindicated as described in the SOPH-A-PORT® Mini S IDDD Instructions for Use, including:

1. The patient has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT ® Mini S device

2. The patient's body size is too small to support the size of the SOPH-A-PORT ® Mini S Access Port, as judged by the Investigator

3. The patient's drug therapy requires substances known to be incompatible with the materials of construction

4. The patient has a known or suspected local or general infection

5. The patient is at risk of abnormal bleeding due to a medical condition or therapy

6. The patient has one or more spinal abnormalities that could complicate safe implantation or fixation

7. The patient has a functioning CSF shunt device

8. The patient has shown an intolerance to an implanted device

7. The patient is unable to comply with the protocol (eg, is unable to return for safety evaluations, or is otherwise unlikely to complete the study) as determined by the Investigator

• All treated patients in Study HGT-SAN-093 will have their cognitive development assessed at the Week 48 Visit in Study HGT-SAN-093. If a decline from Baseline of 20 points or less in the BSID-III DQ score is observed, then the patient may proceed into the Study SHP-610-201 without further evaluation. If a decline from Baseline of more than 20 points in DQ score is observed, then an individual evaluation by the Investigator will occur to determine if the patient is a treatment failure. This individual evaluation will take into account the DQ scores, VABS-II score, physical status, and any other information available for that patient at that time. If the Investigator deems the patient to be a treatment failure, then the patient may not enter the Study SHP-610-201

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 48 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

University of Minnesota

Minneapolis, Minnesota, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Chu Bicetre, Le Kremlin-Bicêtre

Paris, , France

Universitätsklinikum Hamburg Eppendorf

Hamburg, , Germany

Azienda Socio Sanitaria Territoriale - Asst di Monza

Monza, , Italy

Academisch Medisch Centrum Amsterdam

Amsterdam, , Netherlands

Hospital Universitario Vall D'hebron - Ppds

Barcelona, , Spain

Great Ormond Street Hospital

London, , United Kingdom

Countries

United States; France; Germany; Italy; Netherlands; Spain; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2014-003960-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

SHP610-201

Identifier Type: -

Identifier Source: org_study_id